Development of a Risk Prediction Screening Tool for Opioid-Prescription Injury (STOP Injury) in Older Adults Initiated on Opioids From the Emergency Department

Opioid Use Clinical Trial

— STOP Injury  

Official title:

Development of a Risk Prediction Screening Tool for Opioid-Prescription Injury (STOP Injury) in Older Adults Initiated on Opioids From the Emergency Department

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03836235
• Other study ID #: IRB201802137- N
• Secondary ID: R33AG056540JAX A
• Status: Completed
• Start date: March 4, 2019
• Est. completion date: April 3, 2020

Study information

• Verified date: October 2020
• Source: University of Florida
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The long-term goal of this project is to promote responsible opioid prescribing, immediately improving patient safety and ultimately decreasing healthcare costs by reducing older adult morbidity and mortality due to opioid-related injury. The objective of this pilot project is to gather data to inform the development of the STOP Injury tool and evaluate additional predictive factors and important outcomes relevant to prescription opioids.

Description:

The experience from this project will lay the groundwork on prospective validation of STOP Injury in a large appropriately powered study. Aim 1 will provide data that will help narrow inclusion of candidate variables in the STOP Injury tool to include those that are most feasible to collect and most predictive. Aim 2 will help inform the possible inclusion of genetic factors into a predictive model. Finally, Aim 3 will help identify quality of life outcomes that should be considered when assessing opioid medication adverse events.

Aim 1. Evaluate the association between prescription opioid adverse events in older adults and candidate risk prediction variables proposed for STOP Injury prediction score The study team will conduct a pilot prospective observational study of 200 patients 50 years or older who are initiated on opioids from the emergency department (ED). The investigators will analyze the association between candidate risk factors and opioid adverse events (falls and OD).

Aim 2. Evaluate the association between prescription opioid adverse events and genetic factors.

In the cohort from Aim 1, the study team will test subjects for 12 genetic single nucleotide polymorphisms related to opioid metabolism, transport, and effect.

Aim 3. Measure the impact of opioid medications on quality of life measures in older adults The investigators will implement a series of quality of life measures on a subset of patients as a pilot study to determine which measures capture the impact prescription opioids have on older adults' quality of life

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: April 3, 2020
• Est. primary completion date: April 3, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 120 Years

Eligibility

Inclusion Criteria:

• Presenting to UF JAX ED with pain or a pain-related complaint (i.e., fracture, burn, etc.)

• Patient has not used opioids 15 days or more within the last 30 days

• Patient does not have opioid medications at home

• Discharge to home with an opioid prescription

Exclusion Criteria:

• Bed-bound or uses wheelchair

• Living in skilled nursing facility or assisted living facility

• Non-English speaking

• Unable to provide consent

• Incarcerated

• Lack of reliable telephone access

• Use of opioids on most days for >3 months

Related Conditions & MeSH terms

• Emergencies
• Opioid Use

Locations

Country	Name	City	State
United States	UF Health Jacksonville	Jacksonville	Florida

Sponsors (3)

Lead Sponsor	Collaborator
University of Florida	National Institute on Aging (NIA), US Department of Health and Human Services

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety, as measured by number of subjects with at least one fall adverse event	The study team will analyze the association between candidate risk factors and opioid adverse events (falls and OD).	Up to 30 days